Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas
NCT04869449Phase 1Terminated
- Sponsor
- Penn State Health Milton S. Hershey Medical Center
- Start
- May 2022
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ketoconazole in glioblastoma (GBM), sponsored by Penn State Health Milton S. Hershey Medical Center. Primary endpoints: Maximum Plasma Concentration and Half-life. Started May 2022; status: terminated.
02
Drugs
ketoconazole
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04869449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04869449.